Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Internship and Residency | 12 | 2025 | 805 | 3.350 |
Why?
|
| Pancreatic Neoplasms | 11 | 2017 | 341 | 1.870 |
Why?
|
| General Surgery | 5 | 2025 | 211 | 1.740 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 1198 | 1.440 |
Why?
|
| Pancreatitis | 3 | 2020 | 97 | 1.190 |
Why?
|
| Education, Medical, Graduate | 6 | 2025 | 351 | 1.120 |
Why?
|
| Carcinoma, Pancreatic Ductal | 7 | 2015 | 111 | 0.980 |
Why?
|
| Pancreatectomy | 5 | 2016 | 101 | 0.940 |
Why?
|
| Endrin | 1 | 2024 | 3 | 0.870 |
Why?
|
| Mastectomy | 3 | 2024 | 58 | 0.850 |
Why?
|
| Nerve Block | 1 | 2024 | 53 | 0.810 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 26 | 0.610 |
Why?
|
| Social Media | 1 | 2021 | 128 | 0.600 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 149 | 0.590 |
Why?
|
| Databases, Factual | 2 | 2019 | 873 | 0.570 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 115 | 0.550 |
Why?
|
| Students, Medical | 1 | 2020 | 261 | 0.540 |
Why?
|
| Humans | 37 | 2025 | 63461 | 0.510 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 7 | 0.500 |
Why?
|
| Pancreas, Exocrine | 1 | 2016 | 12 | 0.490 |
Why?
|
| Hemangioma | 1 | 2016 | 28 | 0.490 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 19 | 0.480 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 64 | 0.480 |
Why?
|
| Retrospective Studies | 14 | 2024 | 6659 | 0.470 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 102 | 0.450 |
Why?
|
| Genetic Testing | 1 | 2015 | 134 | 0.450 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 159 | 0.430 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 279 | 0.430 |
Why?
|
| Clinical Competence | 4 | 2024 | 727 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2015 | 31 | 0.410 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1309 | 0.410 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 297 | 0.400 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2012 | 5 | 0.390 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 26 | 0.390 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2012 | 4 | 0.380 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 31 | 0.380 |
Why?
|
| Female | 21 | 2025 | 32882 | 0.350 |
Why?
|
| Burnout, Professional | 2 | 2023 | 135 | 0.330 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 36 | 0.320 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 2679 | 0.320 |
Why?
|
| Stomach | 1 | 2010 | 86 | 0.320 |
Why?
|
| Pancreas | 1 | 2010 | 150 | 0.310 |
Why?
|
| Suture Techniques | 1 | 2010 | 101 | 0.310 |
Why?
|
| Hospital Units | 1 | 2008 | 9 | 0.290 |
Why?
|
| Gallstones | 1 | 2008 | 25 | 0.290 |
Why?
|
| Hospital Costs | 1 | 2008 | 126 | 0.270 |
Why?
|
| Personnel Selection | 2 | 2025 | 55 | 0.270 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2462 | 0.260 |
Why?
|
| Patient Admission | 1 | 2008 | 198 | 0.250 |
Why?
|
| Risk Factors | 5 | 2019 | 5354 | 0.250 |
Why?
|
| United States | 7 | 2025 | 7845 | 0.240 |
Why?
|
| Internal Medicine | 2 | 2023 | 160 | 0.240 |
Why?
|
| Male | 17 | 2025 | 29900 | 0.240 |
Why?
|
| Cohort Studies | 4 | 2022 | 2569 | 0.240 |
Why?
|
| Middle Aged | 12 | 2019 | 17601 | 0.240 |
Why?
|
| Specialty Boards | 1 | 2024 | 15 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 59 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 89 | 0.220 |
Why?
|
| Feedback | 1 | 2023 | 93 | 0.200 |
Why?
|
| Educational Measurement | 1 | 2024 | 218 | 0.190 |
Why?
|
| Pandemics | 3 | 2023 | 672 | 0.190 |
Why?
|
| Pain, Postoperative | 1 | 2024 | 163 | 0.190 |
Why?
|
| Preoperative Care | 3 | 2019 | 193 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 5457 | 0.190 |
Why?
|
| Motivation | 1 | 2023 | 284 | 0.180 |
Why?
|
| Prognosis | 4 | 2019 | 1748 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 345 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 2576 | 0.170 |
Why?
|
| Canada | 1 | 2020 | 154 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 937 | 0.160 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 215 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2023 | 1008 | 0.160 |
Why?
|
| Aged | 10 | 2017 | 14436 | 0.160 |
Why?
|
| Veins | 1 | 2020 | 64 | 0.160 |
Why?
|
| Inservice Training | 1 | 2020 | 86 | 0.160 |
Why?
|
| Robotic Surgical Procedures | 1 | 2023 | 161 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2020 | 2080 | 0.160 |
Why?
|
| Research Design | 1 | 2023 | 574 | 0.160 |
Why?
|
| Adult | 9 | 2023 | 16827 | 0.160 |
Why?
|
| Surgical Oncology | 1 | 2019 | 5 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2017 | 5682 | 0.160 |
Why?
|
| Certification | 1 | 2019 | 54 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 96 | 0.150 |
Why?
|
| Learning | 1 | 2020 | 182 | 0.150 |
Why?
|
| Young Adult | 3 | 2016 | 4695 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 40 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 536 | 0.150 |
Why?
|
| Hepatectomy | 1 | 2019 | 63 | 0.150 |
Why?
|
| Incidence | 2 | 2019 | 1377 | 0.140 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 15 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 11 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 422 | 0.140 |
Why?
|
| Mutation | 4 | 2015 | 2609 | 0.130 |
Why?
|
| Lymphoscintigraphy | 1 | 2016 | 6 | 0.130 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 13 | 0.130 |
Why?
|
| Methylene Blue | 1 | 2016 | 22 | 0.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 41 | 0.130 |
Why?
|
| Coloring Agents | 1 | 2016 | 54 | 0.130 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 674 | 0.130 |
Why?
|
| Curriculum | 1 | 2020 | 598 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 495 | 0.120 |
Why?
|
| Neoplasm, Residual | 2 | 2013 | 44 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2015 | 12 | 0.120 |
Why?
|
| Diet | 1 | 2019 | 526 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 21 | 0.110 |
Why?
|
| ras Proteins | 1 | 2015 | 77 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 443 | 0.110 |
Why?
|
| Time Factors | 3 | 2019 | 3770 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 219 | 0.100 |
Why?
|
| Nomograms | 1 | 2013 | 18 | 0.100 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2013 | 4 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 325 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 35 | 0.100 |
Why?
|
| Melanoma | 1 | 2016 | 331 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 322 | 0.090 |
Why?
|
| New England | 2 | 2023 | 274 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2012 | 240 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 87 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 200 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 719 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 412 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 507 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 730 | 0.080 |
Why?
|
| Adolescent | 2 | 2012 | 6252 | 0.080 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 9 | 0.080 |
Why?
|
| Pancreatic Fistula | 1 | 2010 | 18 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2012 | 210 | 0.080 |
Why?
|
| Survival Rate | 1 | 2012 | 852 | 0.080 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 114 | 0.080 |
Why?
|
| Carrier State | 1 | 2009 | 18 | 0.080 |
Why?
|
| Siblings | 1 | 2009 | 44 | 0.080 |
Why?
|
| Logistic Models | 2 | 2013 | 1277 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1364 | 0.070 |
Why?
|
| Pedigree | 1 | 2009 | 193 | 0.070 |
Why?
|
| Cholangiography | 1 | 2008 | 42 | 0.070 |
Why?
|
| Cholecystectomy | 1 | 2008 | 34 | 0.070 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 47 | 0.070 |
Why?
|
| Medicare | 1 | 2012 | 612 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 410 | 0.070 |
Why?
|
| Family | 1 | 2009 | 238 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 311 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 314 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1469 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 338 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2008 | 430 | 0.050 |
Why?
|
| Nipples | 1 | 2023 | 15 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2186 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 55 | 0.050 |
Why?
|
| Income | 1 | 2023 | 169 | 0.050 |
Why?
|
| Self Report | 1 | 2023 | 375 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 1644 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 46 | 0.040 |
Why?
|
| Students | 1 | 2022 | 217 | 0.040 |
Why?
|
| Mammography | 1 | 2021 | 281 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 37 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 92 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 956 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 88 | 0.030 |
Why?
|
| Mice | 1 | 2010 | 10844 | 0.030 |
Why?
|
| Chromogranins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 866 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 214 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 220 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 313 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 278 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 418 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 509 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 74 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 978 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1148 | 0.020 |
Why?
|
| Health Services | 1 | 2012 | 82 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 206 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 9 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1172 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1653 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 72 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 190 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 111 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 1186 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3290 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 1361 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 20660 | 0.010 |
Why?
|